Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This entry represents a combination of four antimalarial drugs: atovaquone, proguanil, artesunate, and mefloquine. The provided information indicates that a specific product combining all four is not mentioned in the search results. Combinations discussed include atovaquone-proguanil (Malarone), and the addition of artesunate to atovaquone-proguanil has been studied for multidrug-resistant *Plasmodium falciparum* malaria with high cure rates. Mefloquine is typically used as a separate antimalarial or as follow-on treatment after initial therapy like IV artesunate. These medications are used in various combinations or sequentially based on clinical factors, resistance patterns, and region.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on atovaquone + proguanil + artesunate + mefloquine.